Qiagen N.V.

ots Ad hoc-Service: Qiagen N.V. QIAGEN REPORTS FOURTH-QUARTER AND FISCAL 2000 YEAR-END RESULTS

Ad hoc-announcement edited and sent by DGAP. The sender is solely responsible for the contents of this announcement. ----------------------------------------------------- Venlo, The Netherlands (ots Ad hoc-Service) - QIAGEN REPORTS FOURTH-QUARTER AND FISCAL 2000 YEAR-END RESULTS QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA, Easdaq: QGEN) reports a successful fourth quarter and fiscal 2000 as well as expansion of its market and technology leadership. The Company reported that consolidated net sales for its fourth quarter increased 29% to $55.8 million, from $43.3 million for the same period in 1999. Excluding the effect of purchased in-process research and development costs related to the acquisition of Rapigene Inc. during the fourth quarter of 1999, operating income for the fourth quarter 2000 increased 34% to $11.0 million from $8.2 million in the comparable period in 1999, and net income for the quarter ended December 31, 2000 increased 10% to $6.6 million from $6.0 million in the same quarter of 1999. Diluted earnings per share excluding the acquisition charge increased 25% to $0.05 (based on 144.4 million average shares and share equivalents outstanding) from $0.04 (based on 142.0 million average shares and share equivalents outstanding) in the comparable quarter of 1999. Excluding the costs related to the activities at QIAGEN Genomics (formerly Rapigene Inc.) in addition to the acquisition charges, operating income for the fourth quarter 2000 increased 55% to $12.7 million from $8.2 million in the comparable period in 1999, net income for the fourth quarter ended December 31, 2000 increased 30% to $7.8 million from $6.0 million in the same quarter of 1999. For fiscal 2000, net sales increased 29% to $204.0 million from $158.2 million in fiscal 1999. Operating income for the year ended December 31, 2000 increased 50% to $34.9 million from $23.3 million in 1999, and net income increased 45% to $20.1 million in 2000 from $13.9 million in 1999. Diluted earnings per share for fiscal 2000 increased 40% to $0.14 (based on 144.2 million average shares and share equivalents) from $0.10 (based on 141.3 million average shares and share equivalents). Contacts: QIAGEN N.V Peer M. Schatz Chief Financail Officer +49 (0)2103 29 11710 e-mail: p.schatz@de.qiagen.com End ----------------------------------------------------- Internet: http://recherche.newsaktuell.de Original-Content von: Qiagen N.V., übermittelt durch news aktuell

Themen in dieser Meldung


Das könnte Sie auch interessieren: